Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 10/20 | 0.68 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.62 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.62 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.62 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.53 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21839549 | 1.00 | NT5E (0.68) | NT5EPRKAG1PRKAA1PRKAB1RNASEL | |
| SCHEMBL30394507 | 1.00 | NT5E (0.68) | NT5EPRKAG1PRKAA1PRKAB1RNASEL | |
| SCHEMBL21839730 | 0.92 | NT5E (0.79) | NT5EPRKAG1PRKAA1PRKAB1DNPH1 | |
| SCHEMBL30394683 | 0.92 | NT5E (0.79) | NT5EPRKAG1PRKAA1PRKAB1DNPH1 | |
| SCHEMBL21839512 | 0.92 | NT5E (0.67) | NT5EPRKAG1PRKAA1PRKAB1RNASEL | |
| SCHEMBL21839513 | 0.92 | NT5E (0.67) | NT5EPRKAG1PRKAA1PRKAB1RNASEL | |
| SCHEMBL30394718 | 0.92 | NT5E (0.67) | NT5EPRKAG1PRKAA1PRKAB1RNASEL | |
| SCHEMBL23907544 | 0.88 | PRKAG1 (0.61) | NT5EPRKAG1PRKAA1PRKAB1DNPH1 | |
| SCHEMBL21839635 | 0.88 | NT5E (0.64) | NT5EPRKAG1PRKAA1PRKAB1DNPH1 | |
| SCHEMBL21839636 | 0.88 | NT5E (0.64) | NT5EPRKAG1PRKAA1PRKAB1DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885PRKAG1 438/4885PRKAA1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.